Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: FDA Approves Updates to Genentech’s Susvimo® (Ranibizumab) for nAMD

Jul 8, 2024

On 8 July 2024, Genentech announced that the FDA has approved the relaunch of Susvimo®, a refillable ocular implant containing a specialised formulation of ranibizumab, which is used for treating nAMD.

The FDA first approved Susvimo® in October 2021.  However, in October 2022, Genentech launched a voluntary recall after test results showed some implants did not perform to Genentech’s standards.  Genentech has now updated the Susvimo® implant and refill needle, and reports that testing confirms the performance standards are met.